RK-582

Developed for: metastasis from malignant tumor of colon
Investigated by: Eiji Shinozaki · Japan Agency for Medical Research and Development

today NCT06853496 · Ph 1

20262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT06853496	Mar 2025 → Mar 2027 expected	metastasis from malignant tumor of colon	Eiji Shinozaki	Recruiting	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	RK-582	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06853496 ↗
Action	Inhibit	“RK-582 selectively inhibited tankyrase” NCT06853496 ↗